Merocit (meropenem): Uses, Dosage & Side Effects

What it's for (Indications)

Meropenem is a broad-spectrum carbapenem antibiotic indicated for the treatment of serious bacterial infections caused by susceptible microorganisms.
Its potent activity against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria makes it suitable for complicated infections where other narrower-spectrum antibiotics may not be effective or where multi-drug resistant pathogens are suspected.
Primary indications include complicated intra-abdominal infections (cIAI) in adults and pediatric patients, complicated skin and skin structure infections (cSSSI), and bacterial meningitis in pediatric patients three months of age and older.
It is also used in the treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, and in some cases of febrile neutropenia, though specific indications may vary by regulatory approval.
The selection of meropenem should be guided by susceptibility testing and local epidemiological data to ensure appropriate use and stewardship of this critical antibiotic, especially given its role in treating resistant infections.
Its robust activity against many extended-spectrum beta-lactamase (ESBL)-producing bacteria makes it a crucial agent in managing severe nosocomial infections.
The empirical use of meropenem should be carefully considered, reserving it for situations where less broad-spectrum agents are inappropriate, to mitigate the risk of promoting antibiotic resistance.

Dosage Information

Type	Guideline
Standard	Meropenem is administered intravenously (IV) and its dosage varies significantly depending on the type and severity of the infection, the susceptibility of the causative organism, the patient's renal function, body weight, and age. For adults, typical doses range from 500 mg to 2 g administered every 8 hours. For complicated intra-abdominal infections, a common adult dosage is 1 g IV every 8 hours. For bacterial meningitis or severe nosocomial infections, higher doses such as 2 g IV every 8 hours may be prescribed. Pediatric dosing for children aged 3 months and older is typically based on body weight, often ranging from 10 mg/kg to 40 mg/kg every 8 hours, up to a maximum adult dose. Specific dosage adjustments are crucial for patients with impaired renal function (creatinine clearance less than 50 mL/min) to prevent drug accumulation and potential adverse effects, particularly central nervous system reactions. Meropenem is typically infused over 15 to 30 minutes, or administered as an IV bolus over 3 to 5 minutes. The duration of therapy depends on the infection type and patient response, usually ranging from 5 to 14 days. All dosing regimens must be determined by a healthcare professional based on clinical evaluation and patient-specific factors, adhering strictly to prescribing information.

Type

Guideline

Standard

Meropenem is administered intravenously (IV) and its dosage varies significantly depending on the type and severity of the infection, the susceptibility of the causative organism, the patient's renal function, body weight, and age. For adults, typical doses range from 500 mg to 2 g administered every 8 hours. For complicated intra-abdominal infections, a common adult dosage is 1 g IV every 8 hours. For bacterial meningitis or severe nosocomial infections, higher doses such as 2 g IV every 8 hours may be prescribed. Pediatric dosing for children aged 3 months and older is typically based on body weight, often ranging from 10 mg/kg to 40 mg/kg every 8 hours, up to a maximum adult dose. Specific dosage adjustments are crucial for patients with impaired renal function (creatinine clearance less than 50 mL/min) to prevent drug accumulation and potential adverse effects, particularly central nervous system reactions. Meropenem is typically infused over 15 to 30 minutes, or administered as an IV bolus over 3 to 5 minutes. The duration of therapy depends on the infection type and patient response, usually ranging from 5 to 14 days. All dosing regimens must be determined by a healthcare professional based on clinical evaluation and patient-specific factors, adhering strictly to prescribing information.

Safety & Warnings

Common Side Effects

Like all potent antibiotics, meropenem can cause a range of side effects, which vary in frequency and severity.
Common side effects, generally mild and transient, include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain.
Headache, rash, pruritus, and inflammation or pain at the injection site are also frequently reported.
More serious, albeit less common, adverse effects warrant immediate medical attention.
These include hypersensitivity reactions, ranging from skin rashes to severe anaphylaxis, which can be life-threatening.
Central nervous system (CNS) adverse events, such as seizures, confusion, hallucinations, and paresthesia, are particularly concerning, especially in patients with pre-existing CNS disorders or renal impairment, or when high doses are used.
Hematological abnormalities such as thrombocytopenia, leukopenia, eosinophilia, and positive direct Coombs test have been observed.
Elevated liver enzymes (AST, ALT, alkaline phosphatase), bilirubin, and renal function abnormalities (increased serum creatinine, blood urea nitrogen) may occur.
The use of meropenem can also lead to the overgrowth of non-susceptible organisms, including fungi, and has a significant risk of causing *Clostridioides difficile*-associated diarrhea (CDAD), which can range from mild diarrhea to severe, potentially fatal pseudomembranous colitis.
Patients should be monitored closely for any signs of adverse reactions during and after therapy.

Serious Warnings

Black Box Warning: Meropenem does not carry a formal FDA Black Box Warning. However, several **Serious Warnings** are imperative for safe use and patient management, warranting careful consideration due to their potential for severe, life-threatening outcomes. These include: 1. **Serious Hypersensitivity Reactions:** Life-threatening anaphylaxis and other severe allergic reactions, including severe dermatologic reactions, have been reported. These reactions can occur even with the first dose. Patients with a history of hypersensitivity to other beta-lactam antibiotics (e.g., penicillins, cephalosporins) may be at increased risk due to potential cross-reactivity. Meropenem is contraindicated in patients with a known history of serious hypersensitivity to meropenem or other carbapenems. Careful patient history taking for allergies is paramount, and if an allergic reaction occurs, meropenem must be discontinued immediately and appropriate emergency treatment instituted. 2. **Central Nervous System (CNS) Adverse Reactions:** Seizures, encephalopathy, confusional states, and other CNS adverse events have been observed, particularly in patients with pre-existing CNS disorders (e.g., brain lesions, history of seizures), compromised renal function, or when higher doses of meropenem are administered. These events can be severe and require immediate medical evaluation. Careful monitoring of patients, particularly those with risk factors, is crucial, and dosage adjustments are essential in patients with renal impairment to mitigate the risk of drug accumulation and CNS toxicity. Concomitant use with valproic acid is not recommended due to a significant decrease in valproic acid levels, which can lead to loss of seizure control. 3. ***Clostridioides difficile*-Associated Diarrhea (CDAD):** CDAD has been reported with the use of nearly all antibacterial agents, including meropenem, and its severity can range from mild diarrhea to fatal pseudomembranous colitis. *Clostridioides difficile* produces toxins that can cause significant colonic inflammation and damage. It is essential to consider the diagnosis of CDAD in patients who develop diarrhea during or after meropenem therapy. Prompt diagnosis and initiation of appropriate management, including discontinuation of meropenem if indicated, are crucial to prevent severe complications. These serious warnings highlight the critical need for careful patient selection, vigilant monitoring, and prompt intervention to ensure the safe and effective use of meropenem.
Meropenem should be used with caution, and several warnings are critical for safe administration.
**Hypersensitivity Reactions:** Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving meropenem.
There is a potential for cross-allergenicity with other beta-lactam antibiotics (e.
g.
, penicillins, cephalosporins).
Patients with a history of hypersensitivity to beta-lactams should be carefully evaluated, and meropenem should be avoided if a history of immediate and severe reaction to other beta-lactams is present.
**Central Nervous System (CNS) Reactions:** Seizures and other CNS adverse reactions (e.
g.
, confusion, encephalopathy, myoclonus) have been reported, particularly in patients with pre-existing CNS disorders (e.
g.
, brain lesions, history of seizures), compromised renal function, or when higher doses are administered.
Renal dose adjustments are imperative to minimize this risk.
***Clostridioides difficile*-Associated Diarrhea (CDAD):** CDAD has been reported with nearly all antibacterial agents, including meropenem, and can range in severity from mild diarrhea to fatal colitis.
It is crucial to consider this diagnosis in patients who present with diarrhea following antibiotic administration.
**Development of Drug-Resistant Bacteria:** Prescribing meropenem in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
**Interaction with Valproic Acid:** Concomitant use of meropenem with valproic acid or divalproex sodium is not recommended, as meropenem can significantly decrease valproic acid concentrations, leading to a loss of seizure control.
Renal function monitoring is essential, and dose adjustments are required in patients with renal impairment.
Prolonged use may result in superinfection.
Patients should be closely monitored for these serious adverse events.

How it Works (Mechanism of Action)

Meropenem is a carbapenem antibiotic, belonging to the beta-lactam class of antibacterial agents. Its bactericidal action results from the inhibition of bacterial cell wall synthesis. Meropenem penetrates the bacterial cell wall and binds to specific penicillin-binding proteins (PBPs) located within the cytoplasmic membrane. By binding to these PBPs, meropenem interferes with the transpeptidation step of peptidoglycan synthesis, a crucial component of the bacterial cell wall. This disruption of cell wall integrity leads to defective cell wall formation, osmotic instability, and ultimately bacterial cell lysis and death. Meropenem exhibits broad-spectrum activity against a wide array of Gram-positive, Gram-negative, and anaerobic bacteria. A key characteristic of meropenem, and carbapenems in general, is its high stability to hydrolysis by most bacterial beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases, which often confer resistance to penicillins and cephalosporins. This stability contributes to its efficacy against many multi-drug resistant bacterial strains. However, it is susceptible to carbapenemases, a growing resistance mechanism. The drug's affinity for multiple PBPs (e.g., PBP2, PBP3 in *E. coli*) contributes to its potent bactericidal activity.